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Recently, it was published a prospective study on drug-drug interactions (DDIs) leading to clinical interventions in oncology. [1] Several considerations must be discussed about this issue.
The authors defined potentially clinical relevant DDIs as those leading to clinical interventions. [1] A recent expert consensus conference defined a clinically relevant potential DDI as a potential DDI with safety concerns related to either toxicity or loss of efficacy that warrants the attention of healthcare professionals and/or systems involved in the medication therapy process. [2] Defining the clinical relevance of a DDI is extremely important because of thousands of theoretical, but not clinically relevant, interactions. High-quality evidence to support the existence of many DDIs is lacking, there are few controlled clinical studies conducted in relevant populations, and individual case reports are underreported and often lack information. [2] Furthermore, this expert workgroup recommended a validated systematic approach to assess a potential DDI. [2] There are no guidelines or standards for determining clinical relevance of interactions via consistent systematic evaluation or classification. [2] One possible approach is to check medication for DDI by using an interaction software program also called DDI compendia. Nowadays, several commercial DDI compendia are available. It is advisable that healthcare professionals consult more than just one DDI information reference source to ensure that is indeed safe to use certain drugs concomitantly. [2] Two different compendia (Micromedex and www.drugs.com) were employed by van Leeuwen et al to "maximize accuracy" of the medication review. [1] However, a recent systematic review on interactions between oral antineoplastic agents and concomitant medication was performed by using Micromedex and LexiComp handbook. [3] Moreover, studies have shown that major conflicts exist among drug compendia on drug interactions information such as severity and evidence ratings. [4] So, which compendia are more advisable? Currently there are no evidence supporting any of them respect the others. To illustrate disparities between drug information resources, we assess the consistencies of the DDI identified by van Leeuwen et al drug information resources by making a comparative assessment of the level of severity between five different compendia on DDI and the label information (Table 1) . The DDI were rated as category A (no known interaction), B (minor/no action needed), C (moderate/monitor therapy), D (major/therapy modification); and X (contraindicated/avoid combination). This classification was based on the same used by some compendia. As can be seen, several discrepancies were observed between the different compendia, some of them remarkable. Compendia use differing approaches to identify and evaluate evidence on DDI. It has been reported that the main factors that contributed to the observed discrepancies could be related to different sources of information (journal articles in languages other than English, reports not published by drug companies…) and the different assumptions to extrapolated DDI of one drug to other drugs within the same class. [4] As mentioned above, further research is warranted to provide more evidence for clinical meaningful DDI. Further studies should be conducted to create a standard evaluation tool or selection criteria to standardize the definitions and classifications of DDIs among databases commonly used to identify DDIs. One possible solution, could be the Drug Interaction eVidence Evaluation (DRIVE) instrument when formally validated. [2] In addition, research is needed to examine how frequently these combinations are being prescribed and whether the DDIs actually cause harm to patients. We think that this issue could be a matter of deeper discussion. Grapefruit+Cyclophosphamide/Vin blastine/Doxorubicin/Vincristine/D ocetaxel 
